Multimodality analysis confers a prognostic benefit of a T-cell infiltrated tumor microenvironment and peripheral immune status in patients with melanoma
Abstract
We previously reported results from a phase 1 study testing intratumoral recombinant poliovirus, lerapolturev, in 12 melanoma patients. All 12 patients received anti-PD-1 systemic therapy before lerapolturev, and 11 of these 12 patients also received anti-PD-1 after lerapolturev. In preclinical models lerapolturev induces intratumoral innate inflammation that engages antitumor T cells. In the current study, prelerapolturev and postlerapolturev tumor biopsies and blood were evaluated for biomarkers of response.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Sep 01, 2022
- Source ID
- 10.1136/jitc-2022-005052
Entities
People
- Aaron D. Therien
- April K S Salama
- Darell D. Bigner
- David Boczkowski
- Eda K Holl
- Georgia Beasley
- Junheng Gao
- Karenia Landa
- Maria Angelica Selim
- Matthias Gromeier
- Michael C Brown
- Norma E. Farrow
- Rami N. Al-rohil
- Sin-ho Jung
- Smita K Nair
Organizations
- National Cancer Institute
- National Institutes of Health
- United States Department of Defense